Vanda Pharmaceutical (VNDA) 15.55 $VNDA
USPTO Dismisses Petition for Inter Partes Review of Fanapt® Patent
PR Newswire - Tue Aug 30, 2:00PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board declined the request by Roxane Laboratories, Inc. (Roxane) to institute an inter partes review of U.S. Patent No. 9,138,432 ("the '432 patent"
. The '432 patent was issued by the USPTO in September 2015 and expires in September 2025.
VNDA: 15.55 (+0.26)
39.7% Return Seen to Date on SmarTrend Vanda Pharmaceuticals Call (VNDA)
Comtex SmarTrend(R) - Fri Aug 26, 1:10PM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on May 27th, 2016 at $10.25. In approximately 3 months, Vanda Pharmaceuticals has returned 39.73% as of today's recent price of $14.32.
VNDA: 15.55 (+0.26)
Can The Uptrend Continue for Vanda Pharmaceuticals (VNDA)?
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:38AM CDT
Investors certainly have to be happy with Vanda Pharmaceuticals Inc. (VNDA) and its short term performance
VNDA: 15.55 (+0.26)
Vanda Stock Up on Favorable U.S. Court Ruling for Fanapt
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:00AM CDT
Shares of Vanda Pharmaceuticals (VNDA) surged 20.6% after the U.S. District of Delaware ruled in favor of the company in a patent infringement lawsuit against Roxane Laboratories
ANIP: 59.86 (-1.56), VNDA: 15.55 (+0.26), NVS: 79.38 (+1.11)
Vanda Pharmaceuticals (VNDA) Catches Eye: Stocks Up 20%
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:30AM CDT
Vanda Pharmaceuticals, Inc. (VNDA) shares rose over 20% in the last trading session.
VNDA: 15.55 (+0.26), ANIK: 47.89 (-0.05)
Vanda Patents Found Valid and Infringed in Fanapt® ANDA Litigation
PR Newswire - Thu Aug 25, 1:51PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that Judge Gregory M. Sleet of the United States District Court for the District of Delaware ruled that Roxane Laboratories Inc. (Roxane) infringed U.S. Patent Nos. RE39,198 (the '198 Patent) and 8,586,610 (the '610 Patent) by submitting to the FDA an ANDA seeking permission to market a generic version of Fanapt® before the expiration of Vanda's patents.
VNDA: 15.55 (+0.26)
After Yesterday's Rally of 20.00% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Aug 25, 12:56PM CDT
Vanda Pharmaceuticals (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $11.58 to a high of $15.24. Yesterday, the shares gained 20.0%, which took the trading range above the 3-day high of $12.69 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VNDA: 15.55 (+0.26)
Research Report Initiation on Biotech Stocks -- Agenus, ProNAi Therapeutics, Vanda Pharma, and Genocea Biosciences
PR Newswire - Thu Aug 11, 7:40AM CDT
This morning on Stock-Callers.com we have Biotech industry under review. This segment is focused on new drug developments and clinical researches. Stocks under evaluation are: Agenus Inc. (NASDAQ: AGEN), ProNAi Therapeutics Inc. (NASDAQ: DNAI), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Genocea Biosciences Inc. (NASDAQ: GNCA). Learn more about these stocks by downloading their free report at:
AGEN: 6.14 (-0.05), VNDA: 15.55 (+0.26), GNCA: 5.37 (+0.09), DNAI: 1.81 (unch)
Uptrend Call Working As Vanda Pharmaceuticals Stock Rises 19.6% (VNDA)
Comtex SmarTrend(R) - Thu Aug 11, 1:24AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on May 27th, 2016 at $10.25. In approximately 3 months, Vanda Pharmaceuticals has returned 19.61% as of today's recent price of $12.26.
VNDA: 15.55 (+0.26)
HETLIOZ® is Now Available for the Treatment of Non-24-Hour Sleep-Wake Disorder in Germany
PR Newswire - Mon Aug 01, 6:00AM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that HETLIOZ® (tasimelteon) is now available for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in Germany.
VNDA: 15.55 (+0.26)
Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results
PR Newswire - Wed Jul 27, 3:01PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the second quarter ended June 30, 2016.
VNDA: 15.55 (+0.26)
Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
PR Newswire - Mon Jun 20, 4:00PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that Mihael H. Polymeropoulos, M.D., Vanda's President and CEO, will deliver a corporate presentation at the JMP Securities Life Sciences Conference in New York City on Tuesday, June 21, 2016 at 3:30 p.m. Eastern Time.
VNDA: 15.55 (+0.26)
Vanda Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Fri Jun 03, 6:00AM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that it will deliver a corporate presentation at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 10:00 a.m. Eastern Time.
VNDA: 15.55 (+0.26)
Ulta Salon, FEI and Vanda Pharma rise while Terex slumps
AP - Fri May 27, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:
VRX: 28.76 (-0.36), VNDA: 15.55 (+0.26), GOOGL: 796.87 (+5.47), TEX: 24.38 (+0.35), PANW: 145.18 (+4.52), GOOG: 771.46 (+2.68), VRX.TO: 37.34 (-0.75), APC: 56.49 (+2.95), FEIC: 106.61 (+0.05)
Vanda Pharmaceuticals Rises 9.69% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri May 27, 3:09PM CDT
Vanda Pharmaceuticals (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $9.85 to a high of $10.49. Yesterday, the shares gained 9.7%, which took the trading range above the 3-day high of $9.90 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VNDA: 15.55 (+0.26)
Vanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults
PR Newswire - Thu May 26, 3:30PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Vanda's supplemental New Drug Application (sNDA) for Fanapt®, modifying and expanding the prescribing information (PI) to describe the effectiveness of Fanapt® as a maintenance treatment for schizophrenia in adults. FDA approval was based on the results of the REPRIEVE (Relapse prevention study in patients with schizophrenia) placebo-controlled clinical study which evaluated the long-term maintenance of efficacy and safety of Fanapt®. The study data submitted in the sNDA came from the REPRIEVE study in which Vanda previously reported 79.6% of patients treated with Fanapt® remained relapse free compared to 36.6% for placebo-treated patients.
VNDA: 15.55 (+0.26)
Vanda reports 1Q loss
Automated Insights - Wed May 04, 4:07PM CDT
WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $12.4 million in its first quarter.
VNDA: 15.55 (+0.26)
Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:01PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31, 2016.
VNDA: 15.55 (+0.26)
Vanda Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 4, 2016
PR Newswire - Thu Apr 14, 3:30PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2016 on Wednesday, May 4, 2016, after the market closes.
VNDA: 15.55 (+0.26)
Impending PDUFA Dates Offer Opportunity for Large Move in Pharmaceutical Companies
ACCESSWIRE - Tue Apr 12, 7:46AM CDT
NEW YORK, NY / ACCESSWIRE / April 12, 2016 / Chiasma, Inc. (NASDAQ: CHMA), KemPharm, Inc. (NASDAQ: KMPH), Lipocine Inc. (NASDAQ: LPCN), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) have PDUFA dates scheduled over the next couple of months which could significantly alter the prospects for the companies.
KMPH: 4.64 (+0.20), VNDA: 15.55 (+0.26), LPCN: 3.48 (+0.05), CHMA: 2.51 (+0.05)
USPTO Dismisses Petition for Inter Partes Review of Fanapt® Patent
PR Newswire - Tue Aug 30, 2:00PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board declined the request by Roxane Laboratories, Inc. (Roxane) to institute an inter partes review of U.S. Patent No. 9,138,432 ("the '432 patent"
. The '432 patent was issued by the USPTO in September 2015 and expires in September 2025. VNDA: 15.55 (+0.26)
39.7% Return Seen to Date on SmarTrend Vanda Pharmaceuticals Call (VNDA)
Comtex SmarTrend(R) - Fri Aug 26, 1:10PM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on May 27th, 2016 at $10.25. In approximately 3 months, Vanda Pharmaceuticals has returned 39.73% as of today's recent price of $14.32.
VNDA: 15.55 (+0.26)
Can The Uptrend Continue for Vanda Pharmaceuticals (VNDA)?
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:38AM CDT
Investors certainly have to be happy with Vanda Pharmaceuticals Inc. (VNDA) and its short term performance
VNDA: 15.55 (+0.26)
Vanda Stock Up on Favorable U.S. Court Ruling for Fanapt
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:00AM CDT
Shares of Vanda Pharmaceuticals (VNDA) surged 20.6% after the U.S. District of Delaware ruled in favor of the company in a patent infringement lawsuit against Roxane Laboratories
ANIP: 59.86 (-1.56), VNDA: 15.55 (+0.26), NVS: 79.38 (+1.11)
Vanda Pharmaceuticals (VNDA) Catches Eye: Stocks Up 20%
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:30AM CDT
Vanda Pharmaceuticals, Inc. (VNDA) shares rose over 20% in the last trading session.
VNDA: 15.55 (+0.26), ANIK: 47.89 (-0.05)
Vanda Patents Found Valid and Infringed in Fanapt® ANDA Litigation
PR Newswire - Thu Aug 25, 1:51PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that Judge Gregory M. Sleet of the United States District Court for the District of Delaware ruled that Roxane Laboratories Inc. (Roxane) infringed U.S. Patent Nos. RE39,198 (the '198 Patent) and 8,586,610 (the '610 Patent) by submitting to the FDA an ANDA seeking permission to market a generic version of Fanapt® before the expiration of Vanda's patents.
VNDA: 15.55 (+0.26)
After Yesterday's Rally of 20.00% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Aug 25, 12:56PM CDT
Vanda Pharmaceuticals (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $11.58 to a high of $15.24. Yesterday, the shares gained 20.0%, which took the trading range above the 3-day high of $12.69 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VNDA: 15.55 (+0.26)
Research Report Initiation on Biotech Stocks -- Agenus, ProNAi Therapeutics, Vanda Pharma, and Genocea Biosciences
PR Newswire - Thu Aug 11, 7:40AM CDT
This morning on Stock-Callers.com we have Biotech industry under review. This segment is focused on new drug developments and clinical researches. Stocks under evaluation are: Agenus Inc. (NASDAQ: AGEN), ProNAi Therapeutics Inc. (NASDAQ: DNAI), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Genocea Biosciences Inc. (NASDAQ: GNCA). Learn more about these stocks by downloading their free report at:
AGEN: 6.14 (-0.05), VNDA: 15.55 (+0.26), GNCA: 5.37 (+0.09), DNAI: 1.81 (unch)
Uptrend Call Working As Vanda Pharmaceuticals Stock Rises 19.6% (VNDA)
Comtex SmarTrend(R) - Thu Aug 11, 1:24AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on May 27th, 2016 at $10.25. In approximately 3 months, Vanda Pharmaceuticals has returned 19.61% as of today's recent price of $12.26.
VNDA: 15.55 (+0.26)
HETLIOZ® is Now Available for the Treatment of Non-24-Hour Sleep-Wake Disorder in Germany
PR Newswire - Mon Aug 01, 6:00AM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that HETLIOZ® (tasimelteon) is now available for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in Germany.
VNDA: 15.55 (+0.26)
Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results
PR Newswire - Wed Jul 27, 3:01PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the second quarter ended June 30, 2016.
VNDA: 15.55 (+0.26)
Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
PR Newswire - Mon Jun 20, 4:00PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that Mihael H. Polymeropoulos, M.D., Vanda's President and CEO, will deliver a corporate presentation at the JMP Securities Life Sciences Conference in New York City on Tuesday, June 21, 2016 at 3:30 p.m. Eastern Time.
VNDA: 15.55 (+0.26)
Vanda Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Fri Jun 03, 6:00AM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that it will deliver a corporate presentation at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 10:00 a.m. Eastern Time.
VNDA: 15.55 (+0.26)
Ulta Salon, FEI and Vanda Pharma rise while Terex slumps
AP - Fri May 27, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:
VRX: 28.76 (-0.36), VNDA: 15.55 (+0.26), GOOGL: 796.87 (+5.47), TEX: 24.38 (+0.35), PANW: 145.18 (+4.52), GOOG: 771.46 (+2.68), VRX.TO: 37.34 (-0.75), APC: 56.49 (+2.95), FEIC: 106.61 (+0.05)
Vanda Pharmaceuticals Rises 9.69% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri May 27, 3:09PM CDT
Vanda Pharmaceuticals (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $9.85 to a high of $10.49. Yesterday, the shares gained 9.7%, which took the trading range above the 3-day high of $9.90 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VNDA: 15.55 (+0.26)
Vanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults
PR Newswire - Thu May 26, 3:30PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Vanda's supplemental New Drug Application (sNDA) for Fanapt®, modifying and expanding the prescribing information (PI) to describe the effectiveness of Fanapt® as a maintenance treatment for schizophrenia in adults. FDA approval was based on the results of the REPRIEVE (Relapse prevention study in patients with schizophrenia) placebo-controlled clinical study which evaluated the long-term maintenance of efficacy and safety of Fanapt®. The study data submitted in the sNDA came from the REPRIEVE study in which Vanda previously reported 79.6% of patients treated with Fanapt® remained relapse free compared to 36.6% for placebo-treated patients.
VNDA: 15.55 (+0.26)
Vanda reports 1Q loss
Automated Insights - Wed May 04, 4:07PM CDT
WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $12.4 million in its first quarter.
VNDA: 15.55 (+0.26)
Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:01PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31, 2016.
VNDA: 15.55 (+0.26)
Vanda Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 4, 2016
PR Newswire - Thu Apr 14, 3:30PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2016 on Wednesday, May 4, 2016, after the market closes.
VNDA: 15.55 (+0.26)
Impending PDUFA Dates Offer Opportunity for Large Move in Pharmaceutical Companies
ACCESSWIRE - Tue Apr 12, 7:46AM CDT
NEW YORK, NY / ACCESSWIRE / April 12, 2016 / Chiasma, Inc. (NASDAQ: CHMA), KemPharm, Inc. (NASDAQ: KMPH), Lipocine Inc. (NASDAQ: LPCN), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) have PDUFA dates scheduled over the next couple of months which could significantly alter the prospects for the companies.
KMPH: 4.64 (+0.20), VNDA: 15.55 (+0.26), LPCN: 3.48 (+0.05), CHMA: 2.51 (+0.05)
